NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$561.0m

Last Updated

2021/04/11 10:03 UTC

Data Sources

Company Financials

Executive Summary

Pak Fah Yeow International Limited, an investment holding company, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People’s Republic of China, Southeast Asia, North America, the United Kingdom, and internationally. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Pak Fah Yeow International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 239 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 239's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-1.6%

239

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

-25.0%

239

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: 239 underperformed the Hong Kong Pharmaceuticals industry which returned 20.9% over the past year.

Return vs Market: 239 underperformed the Hong Kong Market which returned 29.2% over the past year.


Shareholder returns

239IndustryMarket
7 Day-1.6%0.8%-1.1%
30 Day-1.1%0.7%-1.8%
90 Day-3.7%10.0%3.4%
1 Year-22.6%-25.0%23.0%21.2%33.5%28.6%
3 Year-42.8%-48.9%-14.3%-19.1%4.0%-6.9%
5 Year-43.9%-53.2%79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Pak Fah Yeow International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pak Fah Yeow International undervalued compared to its fair value and its price relative to the market?

0.83x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 239 (HK$1.8) is trading above our estimate of fair value (HK$1.25)

Significantly Below Fair Value: 239 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 239 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.

PE vs Market: 239 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 239's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 239 is good value based on its PB Ratio (0.8x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is Pak Fah Yeow International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pak Fah Yeow International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Pak Fah Yeow International performed over the past 5 years?

-33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 239 is currently unprofitable.

Growing Profit Margin: 239 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 239 is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.

Accelerating Growth: Unable to compare 239's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 239 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).


Return on Equity

High ROE: 239 has a negative Return on Equity (-5.7%), as it is currently unprofitable.


Financial Health

How is Pak Fah Yeow International's financial position?


Financial Position Analysis

Short Term Liabilities: 239's short term assets (HK$178.1M) exceed its short term liabilities (HK$30.7M).

Long Term Liabilities: 239's short term assets (HK$178.1M) exceed its long term liabilities (HK$91.5M).


Debt to Equity History and Analysis

Debt Level: 239's debt to equity ratio (2.7%) is considered satisfactory.

Reducing Debt: 239's debt to equity ratio has reduced from 5.6% to 2.7% over the past 5 years.

Debt Coverage: 239's debt is well covered by operating cash flow (27.8%).

Interest Coverage: 239 is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Dividend

What is Pak Fah Yeow International current dividend yield, its reliability and sustainability?

4.22%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 11 2021Ex Dividend DateJul 05 2021Dividend Pay DateAug 13 202139 days from Ex DividendBuy in the next 84 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 239's dividend (4.22%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.96%).

High Dividend: 239's dividend (4.22%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: 239's dividend payments have been volatile in the past 10 years.

Growing Dividend: 239's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: 239 is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.8yrs

Average board tenure


CEO

Wee Sean Gan (73 yo)

9.58yrs

Tenure

HK$6,400,000

Compensation

Mr. Wee Sean Gan has been the Chief Executive Officer of Pak Fah Yeow International Ltd. since September 1, 2011 and serves as its Executive Chairman. Mr. Gan also serves as an Island Command Vice Presiden...


CEO Compensation Analysis

Compensation vs Market: Wee Sean's total compensation ($USD822.75K) is above average for companies of similar size in the Hong Kong market ($USD230.00K).

Compensation vs Earnings: Wee Sean's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 239's board of directors are seasoned and experienced ( 14.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pak Fah Yeow International Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pak Fah Yeow International Limited
  • Ticker: 239
  • Exchange: SEHK
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$560.952m
  • Shares outstanding: 311.64m
  • Website: https://www.pakfahyeow.com

Number of Employees


Location

  • Pak Fah Yeow International Limited
  • 200 Gloucester Road
  • 11th Floor
  • Wan Chai
  • Hong Kong

Listings


Biography

Pak Fah Yeow International Limited, an investment holding company, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People’s Re...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:03
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.